FDA Delays Effective Date for Estrogen-Androgen Combination Drug Notice
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The notice gives FDA 90 more days before its final decision on certain estrogen-androgen fixed-combination drug products takes effect. The deadline moves from June 26, 2026, to September 24, 2026. Drug manufacturers, distributors, pharmacies, and compliance teams tied to products such as Syntest D.S. and Syntest H.S. get a short extension while FDA reviews issues raised after the earlier notice. No new product standard is created here; the practical change is more time before the prior FDA resolution becomes effective.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extends the effective date of the May 27, 2026 FDA notice by 90 days
- Moves the effective date from June 26, 2026, to September 24, 2026
- Gives FDA more time to review issues raised by interested parties
Obligations
What this law requires
Affected parties should treat the May 27, 2026 FDA notice on estrogen-androgen fixed-combination drug products, including Syntest D.S. and Syntest H.S. Tablets, as becoming effective on September 24, 2026, rather than June 26, 2026.